Scinai Immunotherapeutics Ltd. (SCNI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director | 387k | -- | 1976 |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer | 196k | -- | 1983 |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer | 173k | -- | 1971 |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist | 201k | -- | 1964 |
| Merav Kamensky | Head of Quality Control | -- | -- | -- |
| Dr. Naama Adi Hen | Head of Quality Asurance | -- | -- | -- |
| Ms. Alona Tal | Head of Business Administration | -- | -- | -- |
Scinai Immunotherapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 12, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
April 29, 2025 at 12:00 AM UTC
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
March 11, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission